Daily News Podcast

Rivaroxaban beats aspirin for VTE


 

Both low-dose and full-dose rivaroxaban had superior benefit-risk profiles for extended VTE compared with aspirin. Also today, bone biopsy diagnostics for osteomyelitis vary widely, variation in bacterial drug susceptibility are tied to the risk of TB relapse, and CTA cuts MIs in patients with stable chest pain. Subscribe to the MDedge Daily News wherever you get your podcasts.
Amazon Alexa
Apple Podcasts
Spotify

Recommended Reading

Cardiovascular risk management supported for type 2 diabetes
MDedge Internal Medicine
An epidemic of non-alcoholic fatty liver disease
MDedge Internal Medicine
Sleepio app tied to reducing insomnia, depression
MDedge Internal Medicine
5 digital HIPAA myths
MDedge Internal Medicine
Screen for cervical cancer based on age, risk
MDedge Internal Medicine
Is it time for PCPs to take over chronic HCV?
MDedge Internal Medicine
Rivaroxaban data abound at ESC 2018
MDedge Internal Medicine
New MI definition for infarction vs injury
MDedge Internal Medicine
Lorcaserin shows cardiovascular safety
MDedge Internal Medicine
Lung function decline linked to cardiovascular risk
MDedge Internal Medicine